NeoGenomics (STU:NG9) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NG9 NeoGenomics Inc STU:NG9
77 GF Score
Price €12.75
GF Value €14.55
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:NG9 vs WGS, CDNA, PSNL: Short Percentage of Float Comparison

For the Diagnostics & Research subindustry, NeoGenomics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeoGenomics Short Percentage of Float vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Short Percentage of Float falls into.


STU:NG9
77GF Score
NeoGenomics Inc STU:NG9
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NeoGenomics (STU:NG9) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of €12.75 is trading 12.4% below its estimated GF Value™ of €14.55. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for STU:NG9:

  • Short Percentage of Float:
  • GF Value™: €14.55 vs. price of €12.75 (12.4% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the STU:NG9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
77GF Score

Get the complete analysis for STU:NG9

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.75
Price
€14.55
GF Value